All In Biotech

NDA 019829 · Ge Healthcare

Ceretec

Technetium Tc-99m Exametazime Kit · Injection · Radioactive Diagnostic Agent

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 19, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Dec 30, 1988

Approved uses

2

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

38

14 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 10, 2024.

INDICATIONS AND USAGE Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 7, 1995 Supplement 5 · Efficacy
  • Dec 30, 1988 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • CERETEC · TECHNETIUM TC-99M EXAMETAZIME KIT N/A · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Exametazime Kit" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event13
  • drug ineffective8
  • radioisotope scan abnormal7
  • headache4
  • rash4
  • chills3
  • condition aggravated2
  • dyspnoea2
  • malaise2
  • nausea2
  • unresponsive to stimuli2
  • vasospasm2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20061
20143
20152
20166
20174
20182
20192
20206
20212
20223
20242
20252
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Ge Healthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.